Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$508.34
▼ $8.00 (-1.5%)
Market data updated: 09/19 08:08 PM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$128.84B
Day Range
$505.02 - $518.10
52-Week Range
$374.17 - $560.25
Beta
—
Next Earnings
02.11.2026
Support
$465.00
Resistance
$560.25
VRTX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+31.3% (1Y)
Strengths: 12/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 836.5%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $232.75 vs. price $508.34 (-54.2%)
Fair Value
Signal tension
Growth scores strong (76/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
56
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
8d ago · $512.48
Evidence: Narrative Gap moved from 37 to 8 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 4, 2026
Then
71
$557.96
Now
56
$508.34
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
76
Quality
42
Value
38
Momentum
33
Risk
48
Sentiment
80
Fundamental
79
Institutional
0
Stocks with a similar DNA right now
SCANNING VRTX...
Recent media coverage on **Vertex Pharmaceuticals** has been sparse and unrelated to the company itself, as most headlines focus on unrelated topics—such as biotech sector performance, CRISPR Therapeutics, or unrelated firms like Vortex Energy. The few Vertex-related mentions (e.g., long-term investment comparisons) are brief and lack substantive updates on the company’s operations, pipeline, or financials. No recent, specific news about Vertex’s business, products, or strategic moves is evident in the provided sources.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Vertex Pharmaceuticals. News trend score: 80. Reason: 8 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
29
🎯 Conviction (vs. Emotion)
38
Psychology
45
Fundamentals
79
Technical
33
Valuation
38
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
+13%
Market Narrative
60
Fundamental Reality
38
Narrative Gap
+22
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant herding behavior reflects VRTX’s underperformance relative to peers, consistent with a coordinated sell-off. Elevated euphoria and overconfidence scores—despite negative momentum—highlight a disconnect between valuation and fundamentals, possibly driven by anchoring near resistance. The large narrative gap (37 points) suggests traders overestimate positive narratives (75) relative to observable reality (38). The key question is whether herding will persist or shift as traders reassess the stock’s valuation premium.
Updated: 09/08/2026, 05:13 PM
What could change this?
👥 What the crowd believes
"Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%."
"Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues."
🧠 Market Brain events driving this
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 97/100
🔴 Weakest match
Benjamin Graham — 18/100
🗣️ Why do they disagree?
Based on Walter Bagehot's documented principles, the model estimates that the stock’s very high liquidity score (97) suggests it would likely survive a credit squeeze, and Samuel Armstrong Nelson’s score of 91 reinforces a favorable cycle position. Peter Lynch’s and Morgan Housel’s moderate‑high scores (78 and 75) indicate the model sees growth still unfolding and a quiet compounding potential, though not yet fully reflected in price. Mid‑range scores from Philip Fisher, Thorstein Veblen, Gerald Loeb, and Charles Mackay (around 61‑63) lead the model to view the stock as solid but mixed, while Howard Marks (cycle) at 52 and Jack Schwager at 43 suggest it sits in a neutral part of the market cycle with no clear edge. Finally, the low scores from Jesse Livermore, Howard Marks (risk/valuation), Edgar Lawrence Smith, and both Benjamin Graham frameworks (ranging from 42 down to 18) cause the model to flag significant concerns about trend, risk, valuation and defensive criteria, resulting in a more cautious outlook.
Walter Bagehot
Lombard Street (1873)
🟢 97
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 91
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 78
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 75
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 63
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 62
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 62
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 61
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 52
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 43
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 42
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 42
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 34
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 32
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 18
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
86.2%
Operating Margin
34.8%
Net Margin
32.9%
EBITDA Margin
36.5%
ROE
21.2%
ROA
15.4%
ROIC
—
EPS
$15.46
Cash
$5.08B
Total Debt
—
Current Ratio
2.90
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$508.34
Estimated Fair Value (DCF)
$232.75
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-54.2%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.4%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.4% | $3.52B | $3.23B |
| 2 | 8.4% | $3.82B | $3.22B |
| 3 | 6.4% | $4.07B | $3.14B |
| 4 | 4.5% | $4.25B | $3.01B |
| 5 | 2.5% | $4.35B | $2.83B |
Base FCF (last actual year)
$3.19B
Terminal Value
$68.66B
Present Value of Terminal Value
$44.62B
Enterprise Value
$60.05B
Net Debt
$0
Equity Value
$60.05B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$72.35
Tangible Book Value per Share (Tangible NAV)
$66.49
Sentiment based on basic keywords (not AI) — 8 positive, 9 neutral, 3 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 15.9.2026
Business Wire · 15.9.2026
StockStory · 14.9.2026
Yahoo · 14.9.2026
MarketBeat · 14.9.2026
Yahoo · 14.9.2026
GlobeNewswire · 14.9.2026
Yahoo · 14.9.2026
Vertex Pharmaceuticals (VRTX) currently has a StockIQ AI score of 56/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
VRTX currently scores 56/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, VRTX's estimated fair value is $232.75, which is 54.2% below the current price of $508.34. This is one valuation model among several signals in the fair-value category, not a price target.
VRTX's technical score is 33/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 836.5%; Free cash flow growth: 504.1%; Net income growth: 838.1%.
Based on the real signals StockIQ computed: Estimated fair value: $232.75 vs. price $508.34 (-54.2%); Operating margin is eroding over time; Calmar: 0.43 (3y annualized return 12.4% / max drawdown 29.1%).
StockIQ has no recorded dividend payment history for VRTX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 13 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| van Grunsven Jasper | Grant/Award from Employer | 8.9.2026 | 8,682 | +8,682 | — |
| Ambrose Kristen | Grant/Award from Employer | 28.8.2026 | 5,000 | +5,000 | — |
| SACHS BRUCE I | Gift | 27.8.2026 | 39,000 | -6,000 | — |
| SACHS BRUCE I | Gift | 27.8.2026 | 6,000 | -6,000 | — |
| Sachdev Amit | Grant/Award from Employer | 21.7.2026 | 8,251 | +8,251 | — |
| Tatsis Ourania | Grant/Award from Employer | 21.7.2026 | 8,251 | +8,251 | — |
| Sachdev Amit | Grant/Award from Employer | 21.7.2026 | 66,512 | +8,251 | — |
| Tatsis Ourania | Grant/Award from Employer | 21.7.2026 | 53,572 | +8,251 | — |
| Garber Alan M | Grant/Award from Employer | 15.7.2026 | 31.56 | +31.56 | $475.28 |
| SACHS BRUCE I | Grant/Award from Employer | 15.7.2026 | 99.941 | +99.941 | $475.28 |
| SACHS BRUCE I | Grant/Award from Employer | 15.7.2026 | 15,772 | +100 | $475.28 |
| Garber Alan M | Grant/Award from Employer | 15.7.2026 | 65 | +32 | $475.28 |
| McKechnie Duncan | Open Market Sale | 2.7.2026 | 1,541 | -1,541 | $519.00 |
| Tatsis Ourania | Open Market Sale | 2.7.2026 | 1,500 | -1,500 | $524.99 |
| Tatsis Ourania | Open Market Sale | 2.7.2026 | 45,321 | -1,500 | $524.99 |
| McKechnie Duncan | Open Market Sale | 2.7.2026 | 11,001 | -1,541 | $519.00 |
| Liu Joy | Open Market Sale | 1.7.2026 | 828 | -828 | $502.71 |
| Liu Joy | Open Market Sale | 1.7.2026 | 19,131 | -828 | $502.71 |
| Bozic Carmen | Open Market Sale | 26.6.2026 | 596 | -596 | $482.50 |
| Bozic Carmen | Open Market Sale | 18.6.2026 | 1,020 | -1,020 | $462.17 |
| Bozic Carmen | Open Market Sale | 18.6.2026 | 15,933 | -1,020 | $462.17 |
| Bozic Carmen | Open Market Sale | 15.6.2026 | 4,062 | -4,062 | $450.00 |
| Bozic Carmen | Open Market Sale | 5.6.2026 | 1,745 | -1,745 | $450.00 |
| Bozic Carmen | Open Market Sale | 5.6.2026 | 21,015 | -1,745 | $450.00 |
| Liu Joy | Open Market Sale | 1.6.2026 | 828 | -828 | $439.91 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,659,749 shares short as of 2026-08-31 · vs. 3,942,936 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
65.5% of trading volume this week was short selling, vs. 60.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology